Pharnext Presents a Business Update Webcast on May 20th, 2020

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PARIS, FRANCE / ACCESSWIRE / May 14, 2020 / Pharnext SA (FR0011191287 – ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today confirmed the organization of a webcast to update on its current activities on May 20th, 2020 at 6:00 pm (CET).

During this webcast, David Horn Solomon, Chief Executive Officer, will provide a business update and overview of Pharnext.

Attendees can participate by weblink: https://channel.royalcast.com/webcast/pharnext/20200520_1/ or connect by phone using the following coordinates:

Confirmation Code: Pharnext

Dials-in:
– USA: +1 212 999 6659
– France: +33 (0) 1 7099 4740
– UK: +44 (0) 20 3003 2666

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY(TM). Pharnext identifies and develops synergic combinations of drugs called PLEODRUG(TM). The Company was founded by renowned scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.

Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).

Contacts: 

Pharnext
David Solomon
Chief Executive Officer
contact@pharnext.com
+33 (0)1 41 09 22 30
     

Media Relations (Europe)
Ulysse Communication
Bruno Arabian
+33 (0)6 87 88 47 26
barabian@ulysse-communication.com

Pierre-Louis Germain
+33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
+33 (0)1 81 70 96 30

Financial Communication (France)
Actifin
Stéphane Ruiz
sruiz@actifin.fr
+33 (0)1 56 88 11 15

Investors Relations (U.S.)
Stern Investor Relations, Inc.
Jane Urheim
jane.urheim@sternir.com
+1 212 362 1200


SOURCE: Pharnext via EQS Newswire

View source version on accesswire.com:
https://www.accesswire.com/589896/Pharnext-Presents-a-Business-Update-Webcast-on-May-20th-2020

Staff

Recent Posts

Artificial Intelligence (A.I.) in Life Science: New Survey of 408 Researchers Reveals Split Sentiment, Surging Adoption, and Rising Trust Barriers

ARLINGTON, Va., June 20, 2025 /PRNewswire/ -- New survey data from 408 global scientists and researchers…

4 hours ago

Salem Dentist (Smiles Of Salem) Stands with Veterans in National Push for Better Healthcare Protections

This Fourth of July, Dr. Harbpinder Shevchenko, DMD of Smiles of Salem is going beyond…

4 hours ago

American Textile Company’s Centennial Gala Marks 100 Years of Success!

Pittsburgh Event Celebrates Employees, Partners and a Commitment to Growth DUQUESNE, Pa., June 20, 2025…

4 hours ago

Nihar Gala Launches CareIQ, a Pioneering Remote Patient Monitoring Company, and Releases Inspiring New Book “The Strength to Endure”

SEAFORD, Del., June 20, 2025 /PRNewswire/ -- Acclaimed physician, entrepreneur, and visionary healthcare leader Nihar Gala…

4 hours ago

LevelJump Announces 2024 Financial Results

Toronto, Ontario--(Newsfile Corp. - June 20, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the…

5 hours ago